SphingoTec announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT. Although RRT remains a pivotal measure in treating…
Privacy Policy
1. An overview of data protection
General information
The following information will provide you with an easy to navigate overview of what will happen with your personal data when…
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and…
Diese Seite richtet sich ausschließlich an Beschäftigte im Gesundheitswesen. Wenn Sie fortfahren, bestätigen Sie, dass Sie im Gesundheitswesen tätig sind.
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more…
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific…
New findings support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers. So far, the predictive potential of…
Thank you for your request
We will reach out to you shortly.
SphingoTec GmbH Neuendorfstr. 15 16761 Hennigsdorf
Phone: 03302 205650 Email: info[at]sphingotec.com
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…